Alpha L-Iduronidase (IDUA or EC 3.2.1.76) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Powered by
All the vital news, analysis, and commentary curated by our industry experts.
Alpha L-Iduronidase market pipeline research report provides comprehensive information on the Alpha L-Iduronidase (IDUA or EC 3.2.1.76) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Alpha L-Iduronidase (IDUA or EC 3.2.1.76) targeted therapeutics development with respective active and dormant or discontinued projects.
Key MoA in the Alpha L-Iduronidase Pipeline Market
The key MoA in the Alpha L-Iduronidase pipeline market are Alpha L-Iduronidase Activator and Alpha L-Iduronidase Replacement. Alpha L-Iduronidase Activator has the highest number of pipeline products.
Alpha L-Iduronidase Pipeline Market, by MoA
For more MoA insights, download a free report sample
Key RoA in the Alpha L-Iduronidase Pipeline Market
The key RoA in the Alpha L-Iduronidase pipeline market are intravenous, intracisternal, intracerebral, oral, and parenteral. Intravenous has the highest number of pipeline products.
Alpha L-Iduronidase Pipeline Market, by RoA
For more RoA insights, download a free report sample
Key Molecule Types in the Alpha L-Iduronidase Pipeline Market
The key molecule types in the Alpha L-Iduronidase pipeline market are gene therapy, gene-modified cell therapy, fusion protein, recombinant enzyme, small molecule, oligonucleotide, and recombinant protein.
Alpha L-Iduronidase Pipeline Market, by Molecule Types
For more molecule type insights, download a free report sample
Key Companies in the Alpha L-Iduronidase Pipeline Market
The key companies in the Alpha L-Iduronidase pipeline market are RegenxBio Inc, ArmaGen Inc, BioStrategies LC, Denali Therapeutics Inc, EdiGene Inc, Gain Therapeutics Inc, Immusoft Corp, JCR Pharmaceuticals Co Ltd, Orchard Therapeutics Plc, Ossianix Inc, RainBio Inc, and RegenxBio Inc.
Alpha L-Iduronidase Pipeline Market, by Companies
For more molecule type insights, download a free report sample
Market report overview
Key MoA | Alpha L-Iduronidase Activator and Alpha L-Iduronidase Replacement |
Key RoA | Intravenous, Intracisternal, Intracerebral, Oral, and Parenteral |
Key molecule types | Gene Therapy, Gene-Modified Cell Therapy, Fusion Protein, Recombinant Enzyme, Small Molecule, Oligonucleotide, and Recombinant Protein |
Key companies | RegenxBio Inc, ArmaGen Inc, BioStrategies LC, Denali Therapeutics Inc, EdiGene Inc, Gain Therapeutics Inc, Immusoft Corp, JCR Pharmaceuticals Co Ltd, Orchard Therapeutics Plc, Ossianix Inc, RainBio Inc, and RegenxBio Inc |
Scope
- The report provides a snapshot of the global therapeutic landscape for Alpha L-Iduronidase (IDUA or EC 3.2.1.76)
- The report reviews Alpha L-Iduronidase (IDUA or EC 3.2.1.76) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Alpha L-Iduronidase (IDUA or EC 3.2.1.76) targeted therapeutics and enlists all their major and minor projects
- The report assesses Alpha L-Iduronidase (IDUA or EC 3.2.1.76) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Alpha L-Iduronidase (IDUA or EC 3.2.1.76) targeted therapeutics
Reasons to Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Alpha L-Iduronidase (IDUA or EC 3.2.1.76)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Alpha L-Iduronidase (IDUA or EC 3.2.1.76) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
BioStrategies LC
Denali Therapeutics Inc
EdiGene Inc
Gain Therapeutics Inc
Immusoft Corp
JCR Pharmaceuticals Co Ltd
Orchard Therapeutics Plc
Ossianix Inc
RainBio Inc
RegenxBio Inc
Sigilon Therapeutics Inc
Tega Therapeutics Inc
Table of Contents
Table
Figures
Frequently asked questions
-
What are the key MoA in the Alpha L-Iduronidase pipeline market?
The key MoA in the Alpha L-Iduronidase pipeline market are Alpha L-Iduronidase Activator and Alpha L-Iduronidase Replacement.
-
What are the key RoA in the Alpha L-Iduronidase pipeline market?
The key RoA in the Alpha L-Iduronidase pipeline market are intravenous, intracisternal, intracerebral, oral, and parenteral. Intravenous has the highest number of pipeline products.
-
What are the key molecule types in the Alpha L-Iduronidase pipeline market?
The key molecule types in the Alpha L-Iduronidase pipeline market are gene therapy, gene-modified cell therapy, fusion protein, recombinant enzyme, small molecule, oligonucleotide, and recombinant protein.
-
What are the key companies in the Alpha L-Iduronidase pipeline market?
The key companies in the Alpha L-Iduronidase pipeline market are RegenxBio Inc, ArmaGen Inc, BioStrategies LC, Denali Therapeutics Inc, EdiGene Inc, Gain Therapeutics Inc, Immusoft Corp, JCR Pharmaceuticals Co Ltd, Orchard Therapeutics Plc, Ossianix Inc, RainBio Inc, and RegenxBio Inc.
Get in touch to find out about multi-purchase discounts
reportstore@globaldata.com
Tel +44 20 7947 2745
Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.